Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase III Clinical Trial

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 05514054
Trial Status: Call Proj Mgr

Learn more about this clinical trial.

Participating Locations